Human papillomavirus type 16 major capsid protein L1 (HPV16 L1) (HPV16 L1)

The Human papillomavirus type 16 (HPV16) major capsid protein L1 is the primary structural component of the HPV16 virion and the central target for prophylactic vaccines (Source: UniProt, P03101). It self-assembles into pentamers known as capsomeres, which further organize into virus-like particles (VLPs) that are highly immunogenic. The B-cell epitopes located on the surface-exposed loops of the L1 protein—specifically the BC, DE, EF, FG, and HI loops—are the critical sites recognized by neutralizing antibodies (Source: PubMed, PMID: 23935953). These antibodies prevent the virus from interacting with heparin sulfate proteoglycans on the host cell basement membrane, effectively blocking viral entry into basal keratinocytes. Because HPV16 is the leading cause of cervical, oropharyngeal, and other anogenital cancers, targeting these L1 epitopes via vaccination is a cornerstone of global cancer prevention strategies (Source: NCI, HPV and Cancer). Current vaccines, such as Gardasil 9 and Cervarix, utilize recombinant L1 VLPs to elicit a robust and long-lasting humoral immune response against these specific epitopes (Source: FDA, Gardasil 9 Label). These vaccines are highly effective at preventing initial infection but do not provide therapeutic benefit for individuals with pre-existing HPV-related lesions (Source: CDC, HPV Vaccine Safety).

Other names

HPV16 L1Major capsid protein L1HPV-16 L1 proteinHuman papillomavirus type 16 L1-specific B-cell epitopesL1 VLP

Vaccine-induced neutralizing antibodies bind to conformational B-cell epitopes on the L1 protein, preventing the virus from binding to host cell receptors and undergoing endocytosis (Source: PubMed, PMID: 25108344).